SCM
GILD icon

SCS Capital Management’s Gilead Sciences GILD Stock Holding History

SCS Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$835K Buy
6,609
+46
+0.7% +$6.06K 0.01% 311
2026
Q1 		$915K Sell
6,563
-542
-8% -$75.9K 0.01% 286
2025
Q4 		$872K Sell
7,105
-4
-0.1% -$486 0.01% 297
2025
Q3 		$789K Sell
7,109
-506
-7% -$57.5K 0.01% 312
2025
Q2 		$844K Buy
7,615
+7
+0.1% +$745 0.01% 310
2025
Q1 		$853K Buy
+7,608
New +$785K 0.01% 279

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCS Capital Management's GILD Position: Q2 2026 in Review

SCS Capital Management increased its Gilead Sciences (GILD) stake by 0.7% in Q2 2026, buying an estimated $6.06K and bringing the position to 6,609 shares worth $835K. The position accounts for 0.01% of the portfolio, ranked #311.

SCS Capital Management first reported a position in GILD in Q1 2025 and has held it in 6 quarters since. The position peaked at $915K in Q1 2026. 2,283 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • SCS Capital Management held 6,609 shares of Gilead Sciences worth $835K as of Q2 2026.
  • SCS Capital Management bought 46 Gilead Sciences shares in Q2 2026, an estimated $6.06K.
  • Gilead Sciences made up 0.01% of SCS Capital Management's portfolio in Q2 2026, its #311 holding.
  • SCS Capital Management first reported a position in Gilead Sciences in Q1 2025 and has held it in 6 quarters since.
  • SCS Capital Management's Gilead Sciences position peaked at $915K in Q1 2026.
  • 2,283 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on SCS Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.